FRM
CTMX icon

Fox Run Management’s CytomX Therapeutics CTMX Stock Holding History

Fox Run Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,920
Closed -$150K – 997
2026
Q1 		$150K Buy
+33,920
New +$172K 0.03% 802
2018
Q4 		– Sell
-12,149
Closed -$225K – 550
2018
Q3 		$225K Buy
+12,149
New +$277K 0.1% 444
2018
Q2 		– Sell
-15,446
Closed -$439K – 709
2018
Q1 		$439K Buy
+15,446
New +$441K 0.11% 352

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Fox Run Management's CTMX Position: Q2 2026 in Review

Fox Run Management sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 33,920 shares — an estimated $150K sold.

Fox Run Management first reported a position in CTMX in Q1 2018 and held it in 3 quarters. The position peaked at $439K in Q1 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Fox Run Management reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 33,920 CytomX Therapeutics shares in Q2 2026, an estimated $150K.
  • Fox Run Management first reported a position in CytomX Therapeutics in Q1 2018 and held it in 3 quarters.
  • Fox Run Management's CytomX Therapeutics position peaked at $439K in Q1 2018.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.